Brian Cheng
Stock Analyst at JP Morgan
(2.21)
# 2,819
Out of 5,132 analysts
73
Total ratings
43.33%
Success rate
-1.89%
Average return
Main Sectors:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Maintains: Overweight | $49 → $46 | $28.50 | +61.40% | 1 | Feb 2, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $92 → $122 | $96.31 | +26.67% | 2 | Feb 2, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $70 → $125 | $82.34 | +51.81% | 1 | Dec 10, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.23 | - | 1 | Nov 20, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $68 → $81 | $81.49 | -0.60% | 6 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Underweight | $12 → $5 | $11.87 | -57.88% | 5 | Nov 7, 2025 | |
| XNCR Xencor | Maintains: Overweight | $20 → $18 | $11.60 | +55.17% | 5 | Nov 6, 2025 | |
| ZYME Zymeworks | Maintains: Overweight | $20 → $23 | $22.60 | +1.77% | 3 | Oct 16, 2025 | |
| ALLO Allogene Therapeutics | Downgrades: Underweight | n/a | $1.80 | - | 5 | Oct 10, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Underweight | n/a | $1.11 | - | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $2.55 | - | 1 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $33 | $25.75 | +28.16% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $47 | $51.50 | -8.74% | 2 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $20 | $26.45 | -24.39% | 7 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $53.07 | +31.90% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.93 | - | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $22.16 | -0.72% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $23.72 | - | 1 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.76 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $7.26 | +354.55% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.46 | +310.96% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.15 | +9,233.33% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.99 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $320 → $96 | $6.91 | +1,289.29% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.83 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.29 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $7.21 | +1,078.92% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $6.76 | +210.65% | 1 | Aug 3, 2021 |
TG Therapeutics
Feb 2, 2026
Maintains: Overweight
Price Target: $49 → $46
Current: $28.50
Upside: +61.40%
Revolution Medicines
Feb 2, 2026
Maintains: Overweight
Price Target: $92 → $122
Current: $96.31
Upside: +26.67%
Kymera Therapeutics
Dec 10, 2025
Maintains: Overweight
Price Target: $70 → $125
Current: $82.34
Upside: +51.81%
OPKO Health
Nov 20, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.23
Upside: -
Protagonist Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $68 → $81
Current: $81.49
Upside: -0.60%
Intellia Therapeutics
Nov 7, 2025
Downgrades: Underweight
Price Target: $12 → $5
Current: $11.87
Upside: -57.88%
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $20 → $18
Current: $11.60
Upside: +55.17%
Zymeworks
Oct 16, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $22.60
Upside: +1.77%
Allogene Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.80
Upside: -
Pliant Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.11
Upside: -
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $2.55
Upside: -
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $25.75
Upside: +28.16%
Sep 26, 2025
Maintains: Overweight
Price Target: $41 → $47
Current: $51.50
Upside: -8.74%
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $26.45
Upside: -24.39%
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $53.07
Upside: +31.90%
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $4.93
Upside: -
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $22.16
Upside: -0.72%
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $23.72
Upside: -
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.76
Upside: -
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $7.26
Upside: +354.55%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.46
Upside: +310.96%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.15
Upside: +9,233.33%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.99
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $320 → $96
Current: $6.91
Upside: +1,289.29%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $0.83
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $2.29
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $7.21
Upside: +1,078.92%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $6.76
Upside: +210.65%